Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × orantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Lung Neoplasms 1 Kidney Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Sorafenib 203 lenvatinib 129 Bevacizumab 106 Nivolumab 75 atezolizumab 67 pembrolizumab 66 Radiosurgery 58 durvalumab 57 Oxaliplatin 54 Fluorouracil 52 sintilimab 48 Doxorubicin 43 apatinib 41 Hepatectomy 39 tislelizumab 38 camrelizumab 37 Radiofrequency Ablation 36 Leucovorin 36 tremelimumab 34 Radiotherapy 34 Magnetic Resonance Spectroscopy 31 Immune Checkpoint Inhibitors 27 Folfox protocol 26 regorafenib 25 Cyclophosphamide 25 Cisplatin 25 Capecitabine 25 cabozantinib 23 Ipilimumab 23 Gemcitabine 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡